Skip to main content
Clinical Trials/EUCTR2019-004541-33-SE
EUCTR2019-004541-33-SE
Active, not recruiting
Phase 1

A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer. - immvzmpr1

Västra Götalandsregionen0 sites160 target enrollmentJuly 27, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated immunity specifically targeted for varicella and measles, during and after treatment for childhood cancer. We also want to investigate vaccin response for varicella and measles.
Sponsor
Västra Götalandsregionen
Enrollment
160
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 27, 2021
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Children and young people (0\-18\.0 years) who start cancer treatment at the childhood cancer center in Gothenburg.
  • Known vaccination status for measles and chickenpox before start of cancer treatment.
  • Oral and written information for the study and signed consent form.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 160
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Known pre\-existing primary immunodeficiency.
  • Patients planned for relapse therapy or will undergo allogeneic stem cell transplantation (SCT).
  • Known contraindication to any of the suggested vaccines.

Outcomes

Primary Outcomes

Not specified

Similar Trials